keyword
MENU ▼
Read by QxMD icon Read
search

mantle lymphoma

keyword
https://www.readbyqxmd.com/read/29785709/four-year-follow-up-of-a-single-arm-phase-ii-clinical-trial-of-ibrutinib-with-rituximab-ir-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-mcl
#1
Preetesh Jain, Jorge Romaguera, Samer A Srour, Hun J Lee, Frederick Hagemeister, Jason Westin, Luis Fayad, Felipe Samaniego, Maria Badillo, Liang Zhang, Lorreta Nastoupil, Rashmi Kanagal-Shamanna, Nathan Fowler, Michael L Wang
Ibrutinib has shown significant activity in patients with relapsed or refractory mantle cell lymphoma (RR-MCL). We report the long-term outcome and safety profile of a single-centre, single arm, open-label, phase 2 study of RR-MCL treated with IR. Overall, the median follow-up time was 47 months (range 1-52 months), median duration on treatment was 16 months (range 1-53 months) and median number of treatment cycles was 17 (range 1-56). Twenty-nine patients (58%) achieved complete remission and of these, 12 patients continue on study...
May 22, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29784172/mantle-cell-lymphoma-conjunctival-mass-in-a-female-patient
#2
Xinxin Zhang, Kathleen B Gordon, Renzo A Zaldivar, Lamise Z Rajjoub
No abstract text is available yet for this article.
June 2018: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/29779320/-synchronous-lymphoma-and-carcinoma-clinical-analyses-of-17-patients
#3
Y Y Xiong, Z J Liu, L Chen, F F Yuan, Q S Yin, R H Mi, B Zhang, J W Du, Q L Zhang, Q D Lin, L N Zhang, X Gao, L H Dong, Y F Li, Y P Song, X D Wei
Objective: To explore the clinical features of patients with synchronous lymphoma and carcinoma. Methods: The clinical data of 17 patients with Synchronous lymphoma and carcinoma from February 2012 to October 2017 were analyzed retrospectively. Results: Among 17 patients of lymphoma, 1 case HL, 2 cases B-NHL, 6 cases MZBL, 3 cases DLBCL, 1 case mantle cell lymphoma (MCL) , 3 cases NK/T- cell lymphoma, 1 case anaplastic large cell lymphoma(ALCL). In terms of 17 patients with carcinoma, 3 cases esophageal carcinoma, 3 cases gastric carcinoma, 2 cases colorectal carcinoma, 7 cases thyroid carcinoma, 1 case hepatocellular carcinoma and lung cancer...
April 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29771407/association-of-sox11-gene-expression-withclinical-features-and-prognosis-of-mantle-cell-lymphoma
#4
J-X He, Y-F Xi, L-P Su, N Gao, E-W Xu, L-W Xie, L-Y Wang, Y-P Zheng, W-E Han, J Chang, H-W Wang
OBJECTIVE: To study the expression of SOX11 in the patients with mantle cell lymphoma (MCL) and explore the clinical values of SOX11 in MCL. PATIENTS AND METHODS: In the paraffin-embedded MCL tissues of 75 patients diagnosed in the Department of Hematology, Shanxi Tumor Hospital, were performed the immunohistochemical labeling of Ki67 and SOX11 by the EnVision method. Meanwhile, the expression of SOX11 mRNA was also detected by reverse transcriptase-polymerase chain reaction (RT-PCR), and the association of SOX11 with such prognostic indexes as pathological typing, staging, immunophenotyping, and MIPI was analyzed using the statistical method...
May 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29769262/a-new-molecular-assay-and-genomic-complexity-predict-outcome-in-conventional-and-leukemic-non-nodal-mantle-cell-lymphoma
#5
Guillem Clot, Pedro Jares, Eva Giné, Alba Navarro, Cristina Royo, Magda Pinyol, David Martín-Garcia, Santiago Demajo, Blanca Espinet, Antonio Salar, Ana Ferrer, Ana Muntañola, Marta Aymerich, Hilka Rauert-Wunderlich, Elaine S Jaffe, Joseph M Connors, Randy D Gascoyne, Jan Delabie, Armando López-Guillermo, German Ott, George W Wright, Louis M Staudt, Andreas Rosenwald, David W Scott, Lisa M Rimsza, Sílvia Beà, Elías Campo
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy but some patients have a very indolent evolution. This heterogeneous course is related, in part, to the different biological characteristics of conventional MCL (cMCL) and the distinct subgroup of leukemic non-nodal MCL (nnMCL). Robust criteria to distinguish these MCL subtypes and additional biological parameters that influence their evolution are not well defined. Herein, we describe a novel molecular assay that reliably distinguishes cMCL and nnMCL using blood samples...
May 16, 2018: Blood
https://www.readbyqxmd.com/read/29765528/metabolic-changes-associated-with-metformin-potentiates-bcl-2-inhibitor-venetoclax-and-cdk9-inhibitor-bay1143572-and-reduces-viability-of-lymphoma-cells
#6
Vineela Chukkapalli, Leo I Gordon, Parameswaran Venugopal, Jeffrey A Borgia, Reem Karmali
Metformin exerts direct anti-tumor effects by activating AMP-activated protein kinase (AMPK), a major sensor of cellular metabolism in cancer cells. This, in turn, inhibits pro-survival mTOR signaling. Metformin has also been shown to disrupt complex 1 of the mitochondrial electron transport chain. Here, we explored the lymphoma specific anti-tumor effects of metformin using Daudi (Burkitt), SUDHL-4 (germinal center diffuse large B-cell lymphoma; GC DLBCL), Jeko-1 (Mantle-cell lymphoma; MCL) and KPUM-UH1 (double hit DLBCL) cell lines...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29755111/genomic-landscape-and-prognostic-analysis-of-mantle-cell-lymphoma
#7
Ping Yang, Weilong Zhang, Jing Wang, Yuanyuan Liu, Ran An, Hongmei Jing
To gain insight into the molecular pathogenesis of patients with mantle cell lymphoma (MCL), next-generation whole-exome sequencing of 16 MCL patients was performed. We identified recurrent mutations in genes that are well known to be functionally relevant in MCL, including ATM (37.5%), TP53 (31.3%), WHSC1 (31.3%), CCND1 (18.8%), NOTCH2 (6.3%), and CDKN2A (6.3%). We also identified somatic mutations in genes for which a functional role in MCL has not been previously suspected. These genes included CCDC15, APC, CDH1, S1PR1, ATRX, BRCA2, CASP8, and NOTCH3...
May 14, 2018: Cancer Gene Therapy
https://www.readbyqxmd.com/read/29738333/sox11-a-key-oncogenic-factor-in-mantle-cell-lymphoma
#8
Renée Beekman, Virginia Amador, Elias Campo
PURPOSE OF REVIEW: SOX11 has emerged as a key transcription factor in the pathogenesis of mantle cell lymphoma (MCL) whereas it is not expressed in normal B cells or virtually in any other mature B-cell neoplasm. This review will examine the role of SOX11 as a biomarker in MCL, the new information on its transcriptional targets, and the mechanisms regulating its expression in MCL. RECENT FINDINGS: SOX11 is highly expressed in conventional MCL, including cyclin D1-negative cases, but it is not expressed in the indolent leukemic nonnodal MCL subtype...
May 5, 2018: Current Opinion in Hematology
https://www.readbyqxmd.com/read/29737219/use-of-acalabrutinib-in-patients-with-mantle-cell-lymphoma
#9
Farrukh T Awan, Wojciech Jurczak
Acalabrutinib, a selective, Bruton tyrosine kinase (BTK) inhibitor, was granted accelerated approval by the FDA on 31 October 2017 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Areas covered: This narrative review provides an overview of acalabrutinib, its use in clinical practice and potential future developments. Expert commentary: BTK inhibitors have demonstrated efficacy in patients with relapsed or refractory MCL. To prepare patients for therapy, all preexisting infections should be diagnosed and treated, and infection prophylaxis undertaken...
May 8, 2018: Expert Review of Hematology
https://www.readbyqxmd.com/read/29732341/comparison-and-evaluation-of-different-treatment-plans-with-ifrt-field-and-6-and-18-mv-energies-in-hodgkin-s-lymphoma-involvement-neck-and-mediastinum
#10
M B Tavakoli, M Maleki, A Akhavan, T Hadisinia, I Abedi, A Amouheidari
Background: Radiotherapy with large mantle field is an effective technique in increasing the risk of secondary cancers among HL (Hodgkin Lymphoma) patients; therefore, it is essential to choose an effective treatment field including the least medical conditions in radiotherapy. Objective: The present study aimed to plan separate fields for neck and mediastinum using various energies, to compare dose distribution with MLC and to block field formation. Materials and Methods: In this study, 3D conformal treatments, Siemens Oncor accelerator equipped with multi-leaf collimator (MLC) were performed to create anterior-posterior fields...
March 2018: Journal of Biomedical Physics & Engineering
https://www.readbyqxmd.com/read/29732004/s55746-is-a-novel-orally-active-bcl-2-selective-and-potent-inhibitor-that-impairs-hematological-tumor-growth
#11
Patrick Casara, James Davidson, Audrey Claperon, Gaëtane Le Toumelin-Braizat, Meike Vogler, Alain Bruno, Maïa Chanrion, Gaëlle Lysiak-Auvity, Thierry Le Diguarher, Jérôme-Benoît Starck, Ijen Chen, Neil Whitehead, Christopher Graham, Natalia Matassova, Pawel Dokurno, Christopher Pedder, Youzhen Wang, Shumei Qiu, Anne-Marie Girard, Emilie Schneider, Fabienne Gravé, Aurélie Studeny, Ghislaine Guasconi, Francesca Rocchetti, Sophie Maïga, Jean-Michel Henlin, Frédéric Colland, Laurence Kraus-Berthier, Steven Le Gouill, Martin J S Dyer, Roderick Hubbard, Mike Wood, Martine Amiot, Gerald M Cohen, John A Hickman, Erick Morris, James Murray, Olivier Geneste
Escape from apoptosis is one of the major hallmarks of cancer cells. The B-cell Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia. Thus, BCL-2 has become an attractive target for therapeutic strategy in cancer, as demonstrated by the recent approval of ABT-199 (Venclexta™) in relapsed or refractory Chronic Lymphocytic Leukemia with 17p deletion...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29728701/ibrutinib-for-bridging-to-allogeneic-hematopoietic-cell-transplantation-in-patients-with-chronic-lymphocytic-leukemia-or-mantle-cell-lymphoma-a-study-by-the-ebmt-chronic-malignancies-and-lymphoma-working-parties
#12
Peter Dreger, Mauricette Michallet, Paul Bosman, Sascha Dietrich, Mohamad Sobh, Ariane Boumendil, Arnon Nagler, Christof Scheid, Jan Cornelissen, Dietger Niederwieser, Lutz Müller, Elizabeth Vandenberghe, Ilaria Scortechini, Helene Schoemans, Niels S Andersen, Jürgen Finke, Domenico Russo, Per Ljungman, Jakob Passweg, Michel van Gelder, Nadira Durakovic, Helene Labussiere-Wallet, Tobias Berg, Gerald Wulf, Wolfgang Bethge, Donald Bunjes, Stefan Stilgenbauer, Maria Elisa Canepari, Michel Schaap, Christopher P Fox, Nicolaus Kröger, Silvia Montoto, Johannes Schetelig
The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients...
May 4, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29726787/role-of-cyclin-dependent-kinase-4-6-inhibitors-in-the-current-and-future-eras-of-cancer-treatment
#13
S Parylo, A Vennepureddy, V Dhar, P Patibandla, A Sokoloff
Cyclin-dependent kinase 4/6 inhibitors, which act by inhibiting progression from the G1 to S phases of the cell cycle, include palbociclib, ribociclib, abemaciclib, and trilaciclib. Palbociclib and ribociclib are currently food and drug administration-approved for use in combination with aromatase inhibitors in postmenopausal women with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Palbociclib is also food and drug administration-approved for use in combination with fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer progressing after endocrine therapy...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29723393/phase-2-trial-of-bortezomib-in-combination-with-rituximab-plus-hyperfractionated-cyclophosphamide-vincristine-doxorubicin-and-dexamethasone-alternating-with-bortezomib-rituximab-methotrexate-and-cytarabine-for-untreated-mantle-cell-lymphoma
#14
Jorge E Romaguera, Michael Wang, Lei Feng, Luis E Fayad, Frederick Hagemeister, Peter McLaughlin, M Alma Rodriguez, Michelle Fanale, Robert Orlowski, Larry W Kwak, Sattva Neelapu, Yasuhiro Oki, Barbara Pro, Anas Younes, Felipe Samaniego, Nathan Fowler, Kimberly Hartig, Marisa Valentinetti, Judy Smith, Peggy Ford, Adam Naig, L Jeffrey Medeiros, Hagop M Kantarjian, Andre Goy
BACKGROUND: Although the outcomes of patients with mantle cell lymphoma (MCL) have improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory MCL and has shown additive and/or synergistic effects in preclinical trials with known effective agents. METHODS: This is a report of a prospective phase 2 trial of bortezomib added to rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (BzR-hyperCVAD)/rituximab, high-dose methotrexate, and high-dose cytarabine (BzR-MA) for 95 patients with newly diagnosed MCL...
May 3, 2018: Cancer
https://www.readbyqxmd.com/read/29720207/the-t-14-18-translocation-is-absent-from-endothelial-and-follicular-dendritic-cells-of-follicular-lymphoma-fl-and-shows-heterogeneous-presence-in-preserved-fl-mantle-zones
#15
Perikles Kosmidis, Barbara Mankel, Falko Fend, Patrick Adam
BACKGROUND: The translocation t(14;18)(q32;q21) is the genetic hallmark of follicular lymphoma (FL) and can be observed in 85-90% of cases. Whether the translocation is restricted to cells with germinal center B-cell phenotype or can be observed in other cell types of the microenvironment remains debated. Of interest, cases of associated histiocytic and dendritic cell sarcomas arising in the background of FL have been shown to be clonally related and carry the t(14;18), suggesting a "transdifferentiation" of the malignant FL clone into a neoplasm of a different hematopoietic lineage...
May 2, 2018: Diagnostic Pathology
https://www.readbyqxmd.com/read/29717447/droplet-digital-pcr-for-minimal-residual-disease-detection-in-mature-lymphoproliferative-disorders
#16
Daniela Drandi, Simone Ferrero, Marco Ladetto
Minimal residual disease (MRD) detection has a powerful prognostic relevance for response evaluation and prediction of relapse in hematological malignancies. Real-time quantitative PCR (qPCR) has become the settled and standardized method for MRD assessment in lymphoid disorders. However, qPCR is a relative quantification approach, since it requires a reference standard curve. Droplet digitalTM PCR (ddPCRTM ) allows a reliable absolute tumor burden quantification withdrawing the need for preparing, for each experiment, a tumor-specific standard curve...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29695404/establishment-and-characteristics-of-a-novel-mantle-cell-lymphoma-derived-cell-line-and-a-bendamustine-resistant-subline
#17
Tomoko Takimoto-Shimomura, Hisao Nagoshi, Saori Maegawa, Yuto Fujibayashi, Taku Tsukamoto, Yayoi Matsumura-Kimoto, Yoshimi Mizuno, Yoshiaki Chinen, Shinsuke Mizutani, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Tsutomu Kobayashi, Junya Kuroda
BACKGROUND/AIM: Bendamustine hydrochloride (BH) is a key therapeutic agent for mantle cell lymphoma (MCL), while the mechanism underlying BH-resistance has not been verified. MATERIALS AND METHODS: We compared molecular/biological characteristics of a newly-generated MCL-derived cell line KPUM-YY1 and its BH-resistant subline KPUM-YY1R. RESULTS: The growth-inhibitory IC50 for BH was 20 μM in KPUM-YY1 cells, while cell proliferation was not inhibited by up to 60 μM BH in KPUM-YY1R cells...
May 2018: Cancer Genomics & Proteomics
https://www.readbyqxmd.com/read/29695239/bortezomib-prevents-cytarabine-resistance-in-mcl-which-is-characterized-by-down-regulation-of-dck-and-up-regulation-of-spib-resulting-in-high-nf-%C3%AE%C2%BAb-activity
#18
Catja Freiburghaus, Venera Kuci Emruli, Angelica Johansson, Christian Winther Eskelund, Kirsten Grønbæk, Roger Olsson, Fredrik Ek, Mats Jerkeman, Sara Ek
BACKGROUND: The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance. To elucidate the mechanisms responsible for cytarabine resistance, and to create a tool for drug discovery investigations, we established a unique and molecularly reproducible cytarabine resistant model from the Z138 MCL cell line. METHODS: Effects of different substances on cytarabine-sensitive and resistant cells were evaluated by assessment of cell proliferation using [methyl-14C]-thymidine incorporation and molecular changes were investigated by protein and gene expression analyses...
April 25, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29687879/time-to-treatment-is-an-independent-prognostic-factor-in-aggressive-non-hodgkin-lymphomas
#19
Adam J Olszewski, Thomas Ollila, John L Reagan
In aggressive lymphomas, discrepancies in survival reported from experimental and observational studies may reflect selective non-enrolment of high-risk patients in trials. We examined the association between time from diagnosis to chemotherapy and overall survival in diffuse large B-cell (DLBCL), Burkitt (BL), mantle cell (MCL) and peripheral T-cell lymphoma (PTCL), using National Cancer Data Base records of 130 549 patients treated in 2004-2014. Across the histologies, patients who started chemotherapy within 7 days of diagnosis had more often high International Prognostic Index (IPI) or advanced-stage disease...
April 24, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29682183/application-of-a-double-colour-upconversion-nanofluorescent-probe-for-targeted-imaging-of-mantle-cell-lymphoma
#20
Guang Yang, Yong Cao, Bin Yan, Qiang Lv, Jianbo Yu, Fusheng Zhao, Zhihong Chen, Heran Yang, Mengxi Chen, Zaishun Jin
Upconversion nanoparticles are a new type of fluorescent marker in biomedical imaging that can convert a longer wavelength (such as near-infrared fluorescence) into a shorter wavelength (such as visible light). Mantle cell lymphoma, which is derived from B-cell lymphoma, is a subtype of non-Hodgkin's lymphoma, and the immune phenotype is a mature B-cell phenotype (CD20+, CD5+). To develop the use of nanomaterials as specific markers for the medical imaging of mantle cell lymphoma, we modified the surface of UCNPs by oxidation so that the CD20 or CD5 antibody could covalently attach to the upconversion nanoparticles to form antibody-UCNP conjugates...
March 30, 2018: Oncotarget
keyword
keyword
38851
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"